Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV

Chad J. Achenbach, Kimberly K. Scarsi, Robert L. Murphy

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

In the past 15 years, improvements in the treatment of HIV infection have dramatically reduced morbidity and mortality. Nucleoside reverse transcriptase inhibitors are the backbone of combination antiretroviral therapy for the treatment of HIV. One of the recommended and commonly used therapies in this class is the once-daily fixed-dose combination of abacavir/lamivudine. Clinical studies and practice have shown these drugs to be potent, safe, and easy to use in a variety of settings; however, several recent reports have challenged the safety and efficacy claims among certain patient populations, including those at risk for cardiovascular disease and in those with high viral loads prior to treatment initiation. We reviewed abacavir/lamivudine as a treatment for HIV and discussed limitations of its use due to these controversial issues.

Original languageEnglish (US)
Pages (from-to)1-16
Number of pages16
JournalAdvances in Therapy
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

HIV
Therapeutics
Reverse Transcriptase Inhibitors
Viral Load
Nucleosides
HIV Infections
lamivudine drug combination abacavir
Cardiovascular Diseases
Morbidity
Safety
Mortality
Pharmaceutical Preparations
Population

Keywords

  • Abacavir
  • Antiretroviral therapy
  • Epzicom
  • HIV
  • Lamivudine
  • Nucleoside reverse transcriptase inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV. / Achenbach, Chad J.; Scarsi, Kimberly K.; Murphy, Robert L.

In: Advances in Therapy, Vol. 27, No. 1, 01.01.2010, p. 1-16.

Research output: Contribution to journalReview article

@article{104c3fdea46f43828af1e8a2d7228f05,
title = "Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV",
abstract = "In the past 15 years, improvements in the treatment of HIV infection have dramatically reduced morbidity and mortality. Nucleoside reverse transcriptase inhibitors are the backbone of combination antiretroviral therapy for the treatment of HIV. One of the recommended and commonly used therapies in this class is the once-daily fixed-dose combination of abacavir/lamivudine. Clinical studies and practice have shown these drugs to be potent, safe, and easy to use in a variety of settings; however, several recent reports have challenged the safety and efficacy claims among certain patient populations, including those at risk for cardiovascular disease and in those with high viral loads prior to treatment initiation. We reviewed abacavir/lamivudine as a treatment for HIV and discussed limitations of its use due to these controversial issues.",
keywords = "Abacavir, Antiretroviral therapy, Epzicom, HIV, Lamivudine, Nucleoside reverse transcriptase inhibitor",
author = "Achenbach, {Chad J.} and Scarsi, {Kimberly K.} and Murphy, {Robert L.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1007/s12325-010-0006-9",
language = "English (US)",
volume = "27",
pages = "1--16",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "1",

}

TY - JOUR

T1 - Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV

AU - Achenbach, Chad J.

AU - Scarsi, Kimberly K.

AU - Murphy, Robert L.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - In the past 15 years, improvements in the treatment of HIV infection have dramatically reduced morbidity and mortality. Nucleoside reverse transcriptase inhibitors are the backbone of combination antiretroviral therapy for the treatment of HIV. One of the recommended and commonly used therapies in this class is the once-daily fixed-dose combination of abacavir/lamivudine. Clinical studies and practice have shown these drugs to be potent, safe, and easy to use in a variety of settings; however, several recent reports have challenged the safety and efficacy claims among certain patient populations, including those at risk for cardiovascular disease and in those with high viral loads prior to treatment initiation. We reviewed abacavir/lamivudine as a treatment for HIV and discussed limitations of its use due to these controversial issues.

AB - In the past 15 years, improvements in the treatment of HIV infection have dramatically reduced morbidity and mortality. Nucleoside reverse transcriptase inhibitors are the backbone of combination antiretroviral therapy for the treatment of HIV. One of the recommended and commonly used therapies in this class is the once-daily fixed-dose combination of abacavir/lamivudine. Clinical studies and practice have shown these drugs to be potent, safe, and easy to use in a variety of settings; however, several recent reports have challenged the safety and efficacy claims among certain patient populations, including those at risk for cardiovascular disease and in those with high viral loads prior to treatment initiation. We reviewed abacavir/lamivudine as a treatment for HIV and discussed limitations of its use due to these controversial issues.

KW - Abacavir

KW - Antiretroviral therapy

KW - Epzicom

KW - HIV

KW - Lamivudine

KW - Nucleoside reverse transcriptase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=77950650438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950650438&partnerID=8YFLogxK

U2 - 10.1007/s12325-010-0006-9

DO - 10.1007/s12325-010-0006-9

M3 - Review article

C2 - 20204580

AN - SCOPUS:77950650438

VL - 27

SP - 1

EP - 16

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 1

ER -